Specifically, during the study periods (2013–2016), the prophylactic use of long‐acting G‐CSF in patients with breast cancer receiving neoadjuvant/adjuvant AC (anthracycline plus cyclophosphamide)‐containing chemotherapy became eligible for reimbursement by the NHI from September 2016 in Korea. This evidence concerns the gene CSF3 and breast carcinoma.